Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. by Holland, Richard et al.
Holland, R; Brooksby, I; Lenaghan, E; Ashton, K; Hay, L; Smith, R;
Shepstone, L; Lipp, A; Daly, C; Howe, A; Hall, R; Harvey, I (2007)
Effectiveness of visits from community pharmacists for patients with
heart failure: HeartMed randomised controlled trial. BMJ (Clinical
research ed), 334 (7603). p. 1098. ISSN 0959-8138 DOI: 10.1136/bmj.39164.568183.AE
Downloaded from: http://researchonline.lshtm.ac.uk/7203/
DOI: 10.1136/bmj.39164.568183.AE
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
RESEARCH
Effectiveness of visits from community pharmacists
for patients with heart failure: HeartMed randomised
controlled trial
Richard Holland, senior lecturer in public health medicine,1 Iain Brooksby, medical director,3 Elizabeth
Lenaghan, senior research associate,1 Kate Ashton, senior research associate,1 Laura Hay, specialist
registrar in public health medicine,4 Richard Smith, reader in health economics,1 Lee Shepstone, reader in
medical statistics,1 Alistair Lipp, director of public health,5 Clare Daly, education pharmacist,2 Amanda
Howe, professor of primary care,1 Roger Hall, professor of cardiology,1 Ian Harvey professor of
epidemiology and public health1
ABSTRACT
Objective To test whether a drug review and symptom self
management and lifestyle advice intervention by
community pharmacists could reduce hospital
admissions or mortality in heart failure patients.
Design Randomised controlled trial.
SettingHome based intervention in heart failure patients.
Participants 293 patients diagnosed with heart failure
were included (149 intervention, 144 control) after an
emergency admission.
Intervention Two home visits by one of 17 community
pharmacists within two and eight weeks of discharge.
Pharmacists reviewed drugs and gave symptom self
management and lifestyle advice. Controls received usual
care.
Main outcome measures The primary outcome was total
hospital readmissions at six months. Secondary
outcomes included mortality and quality of life
(Minnesota living with heart failure questionnaire and EQ-
5D).
Results Primary outcome data were available for 291
participants (99%). 136 (91%) intervention patients
received one or two visits. 134 admissions occurred in the
intervention group compared with 112 in the control
group (rate ratio=1.15, 95% confidence interval 0.89 to
1.48; P=0.28, Poisson model). 30 intervention patients
died compared with 24 controls (hazard ratio=1.18, 0.69
to 2.03; P=0.54). Although EQ-5D scores favoured the
intervention group, Minnesota living with heart failure
questionnaire scores favoured controls; neither
difference was statistically significant.
Conclusion This community pharmacist intervention did
not lead to reductions in hospital admissions in contrast
to those found in trials of specialist nurse led
interventions in heart failure. Given that heart failure
accounts for 5% of hospital admissions, these results
present a problem for policy makers who are faced with a
shortage of specialist provision and have hoped that
skilled community pharmacists could produce the same
benefits.
Trial registration number ISRCTN59427925.
INTRODUCTION
Research on the treatment of heart failure focuses on
drug treatment, yet evidence from trials of multidisci-
plinary interventions suggests that education and drug
review interventions are effective at reducing hospital
readmission and mortality.1 Trials to date have gener-
ally used heart failure specialist nurses to deliver these
interventions, almost all involved fewer than 200
patients, andmost were done outside the United King-
dom, although one of the most positive trials was car-
ried out by specialist nurses in Glasgow.2
Unfortunately, few heart failure nurses exist through-
out the UK, so developing local packages of specialist
care equivalent to that in the Glasgow study may be
difficult.2 Equally, using hospital based staff in rural
areas is likely to be inefficient because of time lost in
travel.
Community pharmacists, of whom there are more
than 12 000 in the UK, provide a possible alternative.
They are well placed geographically to provide a local
service.They arehighly trained in therapeutics, used to
dealing with patients on a one to one basis, and skilled
in drugproblems and adherence. Furthermore, theUK
government has been encouraging an extension to the
role of community pharmacists, including indepen-
dent prescribing, medicine use review, and a health
promotion role to provide advice about, among other
things, smoking cessation and diet.3-5 Although phar-
macists seem to be an excellent resource with which to
provide aGlasgow-style intervention, the onlyUKevi-
dence to support their use is from two small studies that
were limited by their size.6 7 We have therefore
assessed a community pharmacist led intervention in
a large randomised controlled trial.
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METHODS
Recruitment and assignment
Researchers recruited patients from three large district
general hospitals. Eligible patients were adults (aged
over 18 years), admitted as an emergency in which
heart failure was an important ongoing clinical condi-
tion, and prescribed two ormore drugs (from any drug
class) on discharge. We excluded patients if they were
living in a residential or nursing home, awaiting sur-
gery for ischaemic or valvular heart disease or heart
transplantation, or had terminal malignancy. We ran-
domised patients to receive the pharmacist inter-
vention or usual care. We used third party telephone
randomisation based on a computer generated ran-
dom allocation sequence. We stratified randomisation
byNewYorkHeartAssociation class (class I/II—no or
mild limitation, III—moderate limitation, or IV—
severe limitation) and recruitment site. We obtained
written informed consent from all participants.
Community pharmacists could participate if they
held a postgraduate qualification in pharmacy practice
or had recent continuing professional development in
therapeutics. These pharmacists were not independent
prescribers and so could not directly modify patients’
drug regimens. All participated in a one day training
course, including lectures on heart failure, heart failure
drugs, exercise, diet, and smoking cessation advice
(contact time=7 hours). More than half of the pharma-
cists attended two evening training events on commu-
nication skills (contact time=4 hours). Additionally, 14
of the 17 study pharmacists had received training in
drug review as part of a previous trial (contact time=14
hours).8 The other three study pharmacists received an
additional one day’s training on drug review.
Intervention
We provided study pharmacists with a copy of the
patient’s discharge letter. The pharmacist then
arranged the home visit, within two weeks of dis-
charge, at a time when they could meet the patient
and any carer(s).Where appropriate, pharmacists edu-
cated the patient/carer about heart failure and their
drugs and gave basic exercise, dietary, and smoking
cessation advice. They also encouraged completion
of simple sign and symptom monitoring diary cards
(including monitoring body weight), removed discon-
tinued drugs (with the patient’s consent), fed back
recommendations to the general practitioner, and fed
back to the local pharmacist any need for a drug adher-
ence aid (for example, aMedidos or Dosett container).
We provided all pharmacists with a detailed manual
describing the expected components of their visit and
asked them to deliver education in line with advice
given in the British Heart Foundation’s booklet Living
with Heart Failure,9 which they left with patients after
the first visit. Pharmacists completed a standardised
visit form during each visit. One follow-up visit
occurred at six to eight weeks after discharge to review
progress and reinforce original advice. We also
recorded a selection of pharmacists’ visits to investi-
gate the intervention’s delivery and the pharmacists’
communication skills.10
Masking and the control group
Thenature of the interventionmeant that no clear “pla-
cebo” could be provided. Participants were told after
randomisation which group they were in. Those in the
control group received usual care.
Outcome data and analysis
The primary outcomewas total emergency admissions
to hospital over six months. Secondary outcomes
included deaths and self assessed quality of life mea-
sured with the EQ-5D (a generic instrument)11 12 and
the Minnesota living with heart failure questionnaire
(a disease specific instrument).13 The EQ-5D gives
scores varying from 1 (perfect health) to −0.59 (worst
imaginable health state) and includes a visual analogue
scale from 100 (perfect health) to 0 (worst imaginable
Table 1 | Baseline comparison of intervention and control group patients. Values are numbers
(percentages) unless stated otherwise
Demographic/clinical variables Intervention group (n=149) Control group (n=144)
Female sex 54 (36.2) 53 (36.8)
Mean (SD) age (years) 77.6 (9.0) 76.4 (9.5)
Living alone 58 (38.9) 52 (36.1)
Mean (SD) abbreviated mental test score* 9.2 (1.0) 9.3 (1.0)
NYHA class (self classification):
I 6 (4.0) 11 (7.6)
II 43 (28.9) 37 (25.7)
III 52 (34.9) 47 (32.6)
IV 48 (32.2) 49 (34.0)
Social class (I, II, IIIN)† 63 (44.1) 76 (54.7)
Mean (SD) No of prescribed items taken daily 7.9 (2.6) 7.7 (2.3)
Drugs at discharge included:
ACE inhibitor/A2RA 118 (79.2) 109 (75.7)
Loop diuretic 144 (96.6) 140 (97.2)
Spironolactone 60 (40.3) 54 (37.5)
β blocker 53 (35.6) 61 (42.4)
Antiarrhythmic 16 (10.7) 19 (13.2)
Warfarin 51 (34.2) 49 (34.0)
Antiplatelet drug 78 (52.3) 76 (52.8)
Digoxin 52 (34.9) 44 (30.6)
Mean (SD) frusemidedose,where applicable (mg) 88.0 (49.0) 87.9 (61.6)
Help with drugs‡ 88 (60.3) 76 (54.3)
Drug adherence aid§ 39 (26.5) 22 (15.5)
Mean (SD) length of stay at baseline (days) (from
HES data)
12.5 (16.0) 12.8 (12.8)
Mean (SD) time from recruitment to discharge
(days) (from HES data)
7.3 (15.5) 7.8 (11.6)
CCU/ICU/HDU admission during baseline
admission¶
11 (7.4) 13 (9.1)
A2RA=angiotensin-2 receptor antagonist; ACE=angiotensin converting enzyme; CCU=coronary care unit;
HES=Hospital Episode Statistics; HDU=high dependency unit; ICU=intensive care unit; NYHA=New York Heart
Association.
*Not recorded for one patient in intervention group.
†Employment details not recorded for four patients in each group and not classifiable for two intervention
patients and one control patient.
‡Not applicable for three intervention and four control patients who were not taking drugs before their baseline
admission.
§Current use of adherence aid not recorded for one patient in each group and not known by one patient in each
group.
¶No data for one patient in control group.
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health). The Minnesota living with heart failure ques-
tionnaire consists of 21 questions each scored from0 to
5. Total scores thus vary from 0 to 105, with higher
scores implying a worse condition, and the question-
naire’s authors consider a change of 5 points to be clini-
cally significant.14 In addition, participants completed
a questionnaire that measures drug adherence (medi-
cation adherence report scale orMARS;RHorne, per-
sonal communication, 2002) and the European heart
failure self care behaviour scale.15 We introduced the
last questionnaire as an additional measure eight
months into recruitment. We also collected data on
primary care activity, including numbers of home vis-
its by general practitioners or nurses, practice atten-
dances by patients, numbers of drugs prescribed, and
telephone calls to or from patients.
Emergency admission data came fromHospital Epi-
sode Statistics. The Office for National Statistics pro-
vided mortality data. We mailed questionnaires up to
three times to participants at three and sixmonths, and
the project coordinator contacted all patients before
sending the questionnaires each time to maximise
response. Because of resource constraints, we collected
primary care data on a subgroup of trial patients (those
within practices containing more than three trial
patients).
We used Poisson regression to compare the number
of readmissions between groups. We analysed mortal-
ity by using survival analysis comparing the two
groups with the Cox proportional hazard ratio. In
both analyses, we made adjustments for the two strati-
fication variables (New York Heart Association class
and recruitment site). We analysed questionnaire data
at sixmonths by using analysis of covariance, adjusting
for baseline scores, New York Heart Association class,
and recruitment site. We used Poisson regression to
compare home visits by general practitioners and
attendance at general practitioner practices, entering
practices into the model as a random effect and adjust-
ing for the two stratification variables.
We analysed patient data according to randomisa-
tion group, irrespective ofwhether or not they received
the intervention as planned (the intention to treat prin-
ciple). We used Stata version 8.0 and set statistical sig-
nificance at the 5% level.
Sample size calculation
Local admissiondata suggested a rate of 0.6 admissions
per heart failure patientwithin sixmonths of discharge.
Previous randomised controlled trials suggested that
this could be reduced by 40% over six months—that
is, from 0.6 to 0.36 admissions.7 16 Sample size calcula-
tions based on a normal approximation to the Poisson
distribution indicated that we needed 306 patients to
confer 80% power to show this reduction at the 5%
significance level (two sided).
RESULTS
Participant flow and follow-up
Figure 1 shows the flow of patients through the trial.
We approached a total of 555 patients to participate
after screening them for eligibility between December
2003 and March 2005. We randomised the 339 (61%)
patients who agreed. We excluded 46 patients after
randomisation because of death before discharge
(n=18), heart failure diagnosis not confirmed (n=17),
discharge to nursing/residential home (n=7), planned
cardiac surgery or terminalmalignancy (n=2), and pre-
viously recruited (n=2). Table 1 shows that the two
groupswere similar at baseline, except that fewer inter-
vention participants were from non-manual social
classes (44% v 55%) and intervention participants
more often used some form of drug adherence aid
(27% v 16%). Two patients moved out of the study
area, so primary outcome data were available for 291
(99%) patients.
Assessed for eligibility (n=1880)
Patients eligible and approached (n=555)
Randomised (n=339)
Allocated to intervention (n=169) Allocated to control (n=170)
Intervention group patients (n=149):
  Received one or more pharmacist visit
    (n=136)
  Did not receive intervention (n=13)
Exclusions (n=1325):
  Did not meet inclusion criteria (n=617)
  Died before recruitment (n=78)
  Not available (n=442)
  Other (n=188)
Non-participants (n=216):
  Refused to participate (n=174)
  Other reason (n=42)
Post-randomisation exclusions (n=20)
Analysed (n=148)
Lost to follow-up (n= 1):
   Moved out of study area (n=1)
Analysed (n=143)Analysis
Lost to follow-up (n= 1):
   Moved out of study area (n=1)
Control group patients (n=144):
  Received no pharmacist heart failure
    visit (n=144)
Post-randomisation exclusions (n=26)
Allocation
Follow-up
Fig 1 | Flow of patients through the study
Table 2 | Number of emergency hospital readmissions by group during sixmonths’ trial follow-up
Group
No of readmissions over 6 months
Total admissions Person years of follow-up0 1 2 3 4 5 6
Control 70 49 13 9 1 0 1 112 64.58
Intervention 72 42 18 12 1 2 1 134 67.18
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Study pharmacists and intervention visits
We recruited 17 study pharmacists. Of 149 patients in
the intervention group, 136 (91%) received first visits.
Seven (5%) patients were unavailable for various rea-
sons, including death or early readmission, and six
(4%) patients or their carers refused to be visited.
Study pharmacists made a median of nine first visits
each. Second visits were carried out for 119 (80%)
patients; most of the losses were the result of death or
readmission. Pharmacists spent an average of 5 hours
53minutes delivering each patient’s intervention. This
time was split reasonably evenly between visits (first
visits mean length 72 minutes, second visits
50 minutes), administration (mean 114 minutes), and
travel (mean 131 minutes). Pharmacists reported that
they provided lifestyle advice (exercise, diet, and salt
restriction advice) to more than 95% of visited patients
and advice on symptom selfmanagement to all but one
patient. Alcohol and smoking cessation advice were
delivered to a lower proportion of patients, as few
smoked (n=6) or drank alcohol (median reported
weekly alcohol intake=0 units). Visits generated a
total of 384 recommendations to general practitioners
(2.8/visited patient), 257 after first visits and 127 after
second visits. Approximately one third of recommen-
dations related to heart failure drugs ormonitoring; the
remainder generally referred to other drug advice or
monitoring. Pharmacists reported that 131 (51%) first
visit recommendations were fully or partly enacted
and 54 (21%) were not enacted; no data were available
on the remaining recommendations.
Number of hospital readmissions
A total of 112 emergency readmissions occurred in the
control group and 134 in the intervention group
(table 2). The Poisson model indicated a non-signifi-
cant 15% increase in the intervention group’s rate of
readmission (rate ratio=1.15, 95% confidence interval
0.89 to 1.48; P=0.28). Including social class and use of a
drug adherence aid in the model, as these differed
between groups at baseline, decreased the rate ratio
slightly (rate ratio=1.08, 0.83 to 1.40; P=0.59).
Secondary outcomes
Mortality—Mortality data were available for all
patients. Fewer deaths occurred in the control group
than in the intervention group (24 v 30). Figure 2
shows the Kaplan-Meier survival graph. The hazard
ratio comparing intervention and control groups was
1.18 (95% confidence interval 0.69 to 2.03; P=0.54).
Quality of life—EQ-5D scores at six months could be
compared for 108 intervention patients and 104 con-
trols (91% of surviving intervention patients and 87%
of surviving controls) (table 3). Whereas intervention
patients’ scores were unchanged, controls’ scores
decreased by 10% (worsened), although the difference
between groups was not significant (adjustedmean dif-
ference=0.07, 95% confidence interval −0.01 to 0.14;
P=0.08). Scores on the visual analogue health scale
improved slightly for both groups, but again did not
differ significantly between groups. Minnesota living
with heart failure questionnaires were completed by
78 intervention patients and 80 control patients at six
months (66% of surviving intervention patients and
67% of surviving controls). Whereas intervention
patients’ scores increased (worsened) slightly, those
for control patients decreased (improved) slightly.
Analysis time (days)
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ng
0 50 100 150 200
0
0.2
0.4
0.6
0.8
1.0
Intervention group
Control group
Log rank test: P=0.51
Cox proportional hazard model (adjusted for
stratification variables): P=0.54
Fig 2 | Kaplan-Meier graph showing time to death in
intervention and control groups
Table 3 | Mean EQ-5D scores, health visual analogue scale (VAS) scores, andMinnesota livingwith health failure questionnaire
(MLHFQ) scores for groups at baseline and at threemonths’ and sixmonths’ follow-up
Intervention group Control group
Adjusted mean difference (95% CI); P value*Score (SD)
No of
respondents Score (SD)
No of
respondents
EQ-5D at baseline† 0.58 (0.32) 147 0.57 (0.34) 144
EQ-5D at 3 months† 0.54 (0.33) 113 0.51 (0.37) 100
EQ-5D at 6 months† 0.58 (0.29) 108 0.52 (0.34) 104 0.07 (−0.01 to 0.14); P=0.08
VAS at baseline† 56.6 (19.0) 143 56.9 (19.6) 140
VAS at 3 months† 58.4 (20.8) 107 52.9 (21.9) 96
VAS at 6 months† 58.2 (19.6) 105 58.6 (19.8) 102 −0.93 (−6.05 to 4.20); P=0.72
MLHFQ at baseline‡ 45.9 (24.4) 139 46.1 (23.9) 136
MLHFQ at 3 months‡ 49.6 (28.4) 85 54.4 (26.4) 71
MLHFQ at 6 months‡ 47.7 (26.3) 78 44.5 (27.9) 80 3.73 (−3.67 to 11.13); P=0.32
*Based on analysis of covariance comparing results at six months adjusted for baseline score, site, and New York Heart Association class.
†High scores imply better health.
‡Low scores imply better health.
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This difference was not significant (adjusted mean dif-
ference=3.73, −3.67 to 11.13; P=0.32).
Drug adherence and behaviour change—Patients in both
groups reported very high levels of adherence at all
times of follow-up; no between group differences
were evident. Final adherence scores were marginally
higher (better) in the intervention group (adjusted
mean difference=0.12 units, −0.48 to 0.73 units;
P=0.68) (table 4). Heart failure behaviour scores
improved in both groups, although the final scores
were non-significantly lower (better) in the inter-
vention group (adjusted mean difference=1.7 units,
−4.9 to 1.5 units, P=0.29) (table 5).
Appropriateness of visit and patient satisfaction—Phar-
macists considered that the first visit was definitely use-
ful for 68 (50%) patients and probably useful for 51
(38%) patients; they considered second visits to be defi-
nitely useful for 37 (31%) patients and probably useful
for 58 (49%). One hundred and two (82% of those sur-
viving) intervention patients responded to the satisfac-
tion questionnaire at three months, of whom 75 (74%)
considered the visits to have been extremely or very
useful.
Primary care data—We included 135 patients from 25
practices in this analysis (70 intervention patients, 65
controls). The intervention seemed to increase pri-
mary care activity both in the home and in the general
practice surgery, and increased numbers of prescrip-
tion items. However, with the exception of general
practitioners’ telephone calls and prescription items,
differences between the groups were not statistically
significant (table 6). Given these findings, we did one
unplanned (post hoc) analysis, which summed all pri-
mary care activity (that is, all home visits, attendances
at general practices, and phone calls). This analysis
suggested that the intervention led to a 17% increase
in primary care activity (rate ratio=1.17, 95% confi-
dence interval 1.06 to 1.29; P=0.002).
DISCUSSION
Principal findings of the study
The results suggest that this community pharmacist
intervention does not lead to reductions in hospital
admissions, in contrast to those found in trials of spe-
cialist nurse led interventions in heart failure.1 Instead,
the intervention may increase emergency hospital
admissions, although this result was not statistically sig-
nificant. Equally, the intervention seemed to lead to a
concomitant increase in primary care activity.
In terms of secondary outcomes, the intervention
had no clear effect on mortality, although deaths were
greater in number in the intervention group. The inter-
vention led to no clear improvement in quality of life or
drug adherence; we saw some indication of improved
self care, but changes were not statistically significant.
Strengths and weaknesses of the study
We believe that the internal validity of this study was
high, with concealed allocation of randomisation, both
groups reasonably equivalent at baseline (with the
exception of differences in social class and use of a
medication adherence aid), and good follow-up of
patients (99% for the primary outcome). However,
patients could not be blinded to treatment group,
which may have biased their responses to question-
naires. The trial deliberately used a large number of
pharmacists and broad inclusion criteria to ensure its
generalisability.
Strengths and weaknesses in relation to other studies
Most non-pharmacological trials in heart failure have
tended to be small (median 180 patients).1 By compar-
ison, this studywas larger (n=293). Earlymeta-analyses
in this area suggested that reductions of 25-40% in
admissions might be possible.17 18 However, more
recent meta-analyses, published after this trial started,
have suggested that such interventions yield more
modest reductions in admissions of approximately 10-
20%.1 This trial did not have a sample size based on this
smaller effect. Our confidence limit around the main
outcome, however, suggests that at best our inter-
vention could lead to either a small decrease (10%) or
a potentially substantial increase (50%) in admissions.
Despite these problems related to sample size, the
finding that the intervention at best had no clear posi-
tive effect did seem to be consistent. Instead, it would
seem to have increased health service activity in both
secondary and primary care with no comparable
health improvement (as measured by quality of life
andmortality). The intervention, although appreciated
by patients, affected their heart failure “self care” only
modestly, if at all. Little gain seemed to be made in
adherence, as patients reported very good adherence
even at baseline, although such self report data should
be considered with some caution.19 Finally, the two
quality of life measures seemed to move in different
Table 4 | Medication adherence report scale (MARS) scores
Time
Intervention group (n=149) Control group (n=144)
Adjusted mean difference
(95% CI); P value*
Mean
(median) No of respondents
Mean
(median)
No of
respondents
Baseline 23.82 (25) 133 23.64 (25) 127
3 months 24.11 (25) 112 24.09 (25) 96
6 months 23.74 (25) 101 23.55 (25) 103 0.12 (−0.48 to 0.73) units;
P=0.68
Scores can range from 5 (very poor adherence) to 25 (perfect adherence).
*Analysis of covariance comparing results at six months adjusted for baseline score, site of recruitment, and
New York Heart Association class.
Table 5 | Europeanheart failure self care behaviour scale scores
Time
Intervention group (n=149) Control group (n=144)
Adjusted mean difference
(95% CI); P value*Score (SD)
No of
respondents Score (SD)
No of
respondents
Baseline 31.1 (8.69) 90 30.6 (9.07) 80
3 months 26.08 (10.04) 60 26.58 (10.47) 50
6 months 26.58 (9.45) 60 28.27 (8.66) 52 −1.7 (−4.9 to 1.5) units;
P=0.29
This questionnaire was included from the mid point of the study, so data are available on only a subset of
participants; scores can range from 12 to 60; low scores imply better self care behaviour.
*Analysis of covariance comparing results at six months adjusted for baseline score, site of recruitment, and
New York Heart Association class.
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directions, with small gains suggested by the EQ-5D
that were not replicated by the Minnesota living with
heart failure questionnaire.
Meaning of the study
One may conjecture about possible explanations for
our failure to detect a positive effect size as large as
40% seen in some studies. One possible explanation
is that the intervention was not delivered as intended.
This seems unlikely, as pharmacists reported deliver-
ing all components of the intervention and this was
corroborated by the substudy, which recorded a sam-
ple of interventions and identified that each compo-
nent was indeed delivered.10 The substudy also
suggested that the pharmacists seemed to use good
consultation styles, as measured by the Henbest and
Stewart rating scale.20 Furthermore, the visits seemed
to be well received by patients, almost all of whom
considered them to have been useful and of the right
length and that the pharmacists had an appropriate
level of knowledge. Nevertheless, a good communica-
tion style alone is unlikely to be sufficient. Indeed, the
interventionwas reasonably brief, and further research
is needed to examine whether more focused inter-
viewing skills of motivating behavioural change or
promoting shared decision making would improve
outcomes for patients.21 22
Our intervention may also have been too late in the
disease course to evoke behaviour change. This study
included a broad mix of heart failure patients, and
many patients may have already made changes to
their behaviour (such as stopping smoking). Equally,
others may have already adapted their lifestyle to
their diagnosis (for example, by reducing their exer-
cise), which potentially would have made them more
resistant to accepting advice. A recent study of a spe-
cialist nurse led intervention also found no overall
effect, but suggested possible effectiveness in newly
diagnosed patients.23
Finally, the pharmacists were not specialists in heart
failure care. Their experience and training in heart fail-
ure were thus necessarily more limited than those of
specialist heart failure nurses. In particular, they were
not trained to titrate drugs such as low dose β blockers,
which has been a feature of the most recent multidisci-
plinary interventions.2 24 This specialist versus general-
ist distinction may be important when considering
interventions in heart failure. This is supported by a
recent meta-analysis, which identified that outcomes
were most favourable when interventions were deliv-
ered by a multidisciplinary specialist cardiac team at
home or in the clinic.25
Unanswered questions and future research
The non-significant findings in this study mean that
definitive conclusions are not possible. The confidence
interval around our primary outcome can not exclude
our intervention causing a modest decrease in admis-
sions. However, the consistency of the results across
the variety of study outcomes suggest that community
pharmacists have no clear effect and may potentially
increase use of health services. This last possibility was
previously suggested by the HOMER trial, also done
by our group.8 In contrast to this trial, HOMER
recruited older patients with any disease. However,
although our HeartMed intervention was focused on
heart failure, pharmacists also gave advice and recom-
mendations on patients’ complete drug regimen, and
indeed over half of their recommendations to general
practitioners related to other conditions. Thus, this trial
adds further evidence to suggest that drug review type
interventions may not necessarily yield positive health
service gains, even when they are focused on one dis-
ease area.26 Whether a more intense version of our
intervention could have yielded more positive effects
is unknown. Equally, other examples exist of inter-
ventions that seem to have the potential to decrease
health service activity but in reality may not affect it
(such as the experience of NHS Direct27) or may even
increase use.28 Such interventions, although often
appreciated by patients, may simply lower the thresh-
old for seeking medical advice, increasing the cost of
health care without concomitant improvements in
health.
Given that heart failure accounts for 5% of hospital
admissions, these results present a problem for policy
makers who are faced with a shortage of specialist pro-
vision yet desire services that are widely available and
can reduce admissions. The next research steps should
be to rigorously evaluate whether initiatives to deliver
specialist care across larger geographical areas have
been successful,29 but also to determine how intense
such services need to be.
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Table 6 | Primary care activity data for subgroup of patients for whom thesewere collected
Intervention
group (n=70)
Control
group
(n=65) Rate ratio* Adjusted rate ratio†
GP home visits 134 99 1.28 (0.97 to 1.68); P=0.08 1.03 (0.77 to 1.37);
P=0.83
Nurse/other visit 84 67 1.13 (0.82 to 1.57); P=0.46 1.05 (0.75 to 1.47);
P=0.76
Practice attendance—
GP
289 263 1.05 (0.88 to 1.26); P=0.56 1.09 (0.90 to 1.30);
P=0.37
Practice attendance—
nurse/other
373 316 1.13 (0.96 to 1.33); P=0.13 1.12 (0.95 to 1.32);
P=0.19
GPphone calls to/from
patient
109 69 1.62 (1.17 to 2.23); P=0.003 1.54 (1.11 to 2.13);
P=0.01
Nurse/otherphonecall
to/from patient
74 35 1.80 (1.17 to 2.75); P=0.007 1.54 (0.98 to 2.42);
P=0.06
Mean (median) drugs
prescribed over
6 months
47.0 (41) 41.0 (38) 1.12 (1.06 to 1.18); P<0.001 1.08 (1.02 to 1.14);
P=0.005‡
GP=general practitioner.
*Participants’ general practice entered as random effect.
†Adjusted for hospital site of recruitment and New York Heart Association Class (stratification variables).
‡Additionally adjusted for number of drugs prescribed at baseline.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Educational and symptom self management interventions can decrease mortality and
readmissions in heart failure patients when delivered by specialist personnel
Specialist staff to deliver such interventions are in short supply
WHAT THIS STUDY ADDS
Patients were very satisfied with an educational and symptom self management intervention
delivered by community pharmacists
This intervention did not lead to reductions in admissions or mortality of the magnitude seen
with specialist interventions
Community pharmacists may not with current training be sufficiently expert to deliver the
type of intervention needed to reduce heart failure admissions and mortality
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